Live attenuated influenza vaccine

Rite Aid Announces Availability of Flu and RSV Vaccine Appointments at All Locations

Retrieved on: 
Friday, August 4, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Vaccine, Communication, Travel, Pacific Northwest, RAD, Rite Aid, COVID-19, CDC, Live attenuated influenza vaccine, Pharmacist, RSV, Centers for Disease Control and Prevention, Rite, NYSE

As August marks Immunization Awareness Month, Rite Aid (NYSE: RAD) today announced appointments for flu and RSV vaccines are available at all store locations, including Bartell Drugs in the Pacific Northwest.

Key Points: 
  • As August marks Immunization Awareness Month, Rite Aid (NYSE: RAD) today announced appointments for flu and RSV vaccines are available at all store locations, including Bartell Drugs in the Pacific Northwest.
  • Customers can now schedule appointments to protect themselves and family members against the upcoming respiratory virus season through Rite Aid’s online scheduler .
  • Rite Aid and Bartell Drugs will provide the new CDC-recommended COVID-19 vaccine once available, which will better protect against the most prevalent COVID-19 strain.
  • To schedule an appointment for a flu vaccine or other immunizations, Rite Aid customers can use the online scheduling tool at riteaid.com.

Rite Aid Opens Online Scheduling for Flu Vaccines at All Locations

Retrieved on: 
Thursday, August 4, 2022
COVID-19, Medical Supplies, Infectious Diseases, Other Retail, Convenience Store, Managed Care, General Health, Pharmaceutical, Health, Retail, Influenza B virus, Travel, Pharmacy, Rite Aid, Industry, NYSE, Pacific Northwest, Communication, Live attenuated influenza vaccine, Bartell Drugs, COVID-19, RAD, Vaccine, Vaccination, Disease management, Time, Health, Pharmacist, Online shopping, Elixir

Rite Aid (NYSE: RAD) has opened online scheduling for flu shots at its locations including Bartell Drugs in the Pacific Northwest, and is now accepting walk-ins, providing convenient options for families to get vaccinated.

Key Points: 
  • Rite Aid (NYSE: RAD) has opened online scheduling for flu shots at its locations including Bartell Drugs in the Pacific Northwest, and is now accepting walk-ins, providing convenient options for families to get vaccinated.
  • With children going back to school, now is the perfect time to schedule a flu shot as well as other needed routine vaccines, said Karen Staniforth, Chief Pharmacy Officer at Rite Aid.
  • To schedule an appointment for a flu vaccine or other immunizations, Rite Aid customers can use the online scheduling tool at riteaid.com.
  • Rite Aid employs more than 6,400 pharmacists and operates more than 2,350 retail pharmacy locations across 17 states.

Global Influenza Vaccines Market Report 2021-2027: Persons Vaccinated, Major Deals, Impact of COVID-19, Company Analysis, Size, Share, Growth, Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Vaccination, Vaccines, Medical specialties, Clinical medicine, Influenza vaccines, Influenza vaccine, Vaccine, Live attenuated influenza vaccine

The "Global Influenza Vaccines Market, Persons Vaccinated, Impact of COVID-19, Company Analysis, Size, Share, Growth, Trends, Major Deals - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Influenza Vaccines Market, Persons Vaccinated, Impact of COVID-19, Company Analysis, Size, Share, Growth, Trends, Major Deals - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global influenza vaccines market is projected to exceed US$ 9.5 Billion mark by 2027, and is presenting ample opportunities to the industry's players.
  • By Region - Influenza Vaccines Market, Persons Vaccinated and Forecast (2011 - 2027)
    4.
  • Country Wise Distribution - Influenza Vaccines Market, Persons Vaccinated and Forecast (2011 - 2027)

X-Vax Technology Appoints Varsha K. Jain, MD as Chief Clinical Development Officer

Retrieved on: 
Wednesday, July 21, 2021
Health care, Medical specialties, Health, Influenza vaccines, Swine flu pandemic, GlaxoSmithKline, Vaccine, Live attenuated influenza vaccine

PALM BEACH GARDENS, Fla., July 21, 2021 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced the appointment of Varsha K. Jain, MD as Chief Clinical Development Officer.

Key Points: 
  • PALM BEACH GARDENS, Fla., July 21, 2021 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced the appointment of Varsha K. Jain, MD as Chief Clinical Development Officer.
  • Previously, Dr. Jain served as Senior Program Officer, Vaccine Development and Surveillance at the Bill and Melinda Gates Foundation.
  • Earlier in her career, she oversaw influenza, herpes and Lyme disease vaccine programs in Global Vaccine Discovery and Development at GlaxoSmithKline (GSK).
  • Reporting to Varsha K. Jain, MD will be Guissou Dabiri, PhD, who joined X-VAX as Head of Scientific Communications, and Michael Schwartz, Head of Clinical Trials Management.

Blue Water Vaccines Announces Exclusive, Global License Agreement of Novel Versatile Vaccine Platform from Cincinnati Children's Hospital Medical Center

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Medicine, Clinical medicine, Vaccination, Vaccines, Virology, Medical research, Vaccine, Virus-like particle, Rotavirus, Live attenuated influenza vaccine, COVID-19 vaccine

CINCINNATI, July 13, 2021 /PRNewswire/ -- Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has licensed a novel virus-like particle (VLP) vaccine platform from Cincinnati Children's Hospital Medical Center (Cincinnati Children's).The platform utilizes nanoparticle delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases.

Key Points: 
  • CINCINNATI, July 13, 2021 /PRNewswire/ -- Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has licensed a novel virus-like particle (VLP) vaccine platform from Cincinnati Children's Hospital Medical Center (Cincinnati Children's).The platform utilizes nanoparticle delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases.
  • Blue Water Vaccines has obtained the exclusive, global license to use the novel platform for vaccine discovery, research, and development.
  • "Blue Water Vaccines is excited to collaborate with the incredible experts at Cincinnati Children's.
  • Blue Water Vaccines intends to apply the technology to developing its revolutionary universal vaccine for influenza and a novel, dual vaccine for norovirus and rotavirus.

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

Retrieved on: 
Friday, July 9, 2021
Health sciences, Health, Medicine, Drug discovery, Rintatolimod, AIM ImmunoTech, Common cold, Rhinovirus, Antiviral drug, Therapy, Live attenuated influenza vaccine, Nasal administration

OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

Key Points: 
  • OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.
  • In an HCT, subjects are intentionally exposed to particular diseases to test how the diseases will respond to potential therapeutics.
  • This Phase 2a study will come in the wake of AIMs recent announcement that all subjects have completed treatment in the companys Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

2021 Report on Seasonal Influenza Vaccines - Market is Expected to Expand Over Next 10 Years - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Vaccination, Health care, Vaccines, Influenza vaccines, Animal virology, Influenza, Influenza vaccine, Live attenuated influenza vaccine, Flu season, Vaccine, Sanofi

The "Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Two types of influenza virus are predominant in humans, types A and B, which circulate annually between late fall and early spring, causing seasonal epidemics.
  • Three major manufacturers dominate the seasonal influenza vaccines market, namely GlaxoSmithKline, Seqirus, and Sanofi, with 2020 vaccines sales of $1,023m, $952m (June 2019 to June 2020), and $2,953m, respectively.
  • Additionally, AstraZeneca's FluMist QIV has recovered its footing in the influenza market, matching its previous peak sales of $295m.

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

Retrieved on: 
Wednesday, July 7, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Vaccines, Vaccination, Drugs, Clinical trials, COVID-19 vaccines, RNA vaccines, Medical research, Moderna, RNA vaccine, Influenza vaccine, Vaccine, Live attenuated influenza vaccine

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Companys quadrivalent seasonal influenza mRNA vaccine candidate.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Companys quadrivalent seasonal influenza mRNA vaccine candidate.
  • This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of mRNA-1010, Modernas seasonal influenza vaccine candidate in healthy adults 18 years and older in the U.S.
  • We are pleased to have begun this Phase 1/2 study of mRNA-1010, our first mRNA seasonal flu vaccine candidate to enter the clinic.
  • We expect that our seasonal influenza vaccine candidates will be an important component of our future combination respiratory vaccines, said Stphane Bancel, Chief Executive Officer of Moderna.

Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology

Retrieved on: 
Monday, June 21, 2021
Health sciences, Health, Life sciences, Zoonoses, Vaccines, Mark R. Dybul, Specialty drugs, Virus, Biopharmaceutical, COVID-19, Food and Drug Administration, Live attenuated influenza vaccine

A request for a Pre-Investigator New Drug meeting for the COVID-19 treatment will be submitted to the FDA in the near term.

Key Points: 
  • A request for a Pre-Investigator New Drug meeting for the COVID-19 treatment will be submitted to the FDA in the near term.
  • In addition, all pandemic influenza viruses since 1918 have a similar region as that targeted by this technology.
  • Dr. Mark Dybul, a prominent expert in HIV and Executive Vice Chairperson of the Board of Enochian BioSciences, said, The current COVID-19 variants are concerning.
  • Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy.

Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)

Retrieved on: 
Thursday, June 17, 2021
Vaccination, Drugs, Vaccines, Medical specialties, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Sanofi, Influenza, Quadrivalent vaccine, Influenza A virus subtype H3N2

The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.

Key Points: 
  • The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.
  • Fluzone High-Dose Quadrivalent is a vaccine indicated for prevention of influenza disease caused by influenza A and B strains contained in the vaccine.
  • Vaccination with Fluzone High-Dose Quadrivalent may not protect all people who receive the vaccine.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.|